/
ANAB
$64.49+$1.34 (+2.12%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$1.8B
29M shares
52-week range
$17.11 – $73.30
84% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.35%
Easy to borrow
Price (6 mo)
Loading chart…
Change+$38.56
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $5.0M | $8.0M | $75.0M | $63.2M | $10.3M | $17.2M | $91.3M | $234.6M |
| Cost of revenue | $56.2M | $99.3M | $80.0M | $98.5M | $88.8M | $132.3M | $163.8M | $2.4M |
| Gross profit | −$51.2M | −$91.3M | −$5.0M | −$35.3M | −$78.5M | −$115.1M | −$72.6M | $232.2M |
| Gross margin | -1023.9% | -1141.7% | -6.7% | -55.9% | -763.2% | -671.0% | -79.5% | 99.0% |
| R&D | $56.3M | $99.3M | $80.0M | $98.5M | $88.8M | $139.6M | $163.8M | $136.0M |
| Operating income | −$66.7M | −$107.4M | −$23.9M | −$56.8M | −$115.2M | −$164.4M | −$114.9M | $47.9M |
| EBITDA | −$59.9M | −$95.9M | −$19.4M | −$55.7M | −$105.3M | −$156.4M | −$92.7M | $69.2M |
| Net income | −$61.7M | −$97.3M | −$19.9M | −$57.8M | −$128.7M | −$163.6M | −$145.2M | −$13.2M |
| Net margin | -1233.1% | -1216.7% | -26.6% | -91.5% | -1251.3% | -953.7% | -159.1% | -5.6% |
| EPS (diluted) | -2.50 | -3.60 | -0.73 | -2.11 | -4.57 | -6.08 | -5.12 | -0.46 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $110M | $-1.52 | $-2.93–$0.89 | 5 |
| 2027 | $154M | $1.96 | $0.63–$2.75 | 5 |
| 2028 | $316M | $8.00 | $5.42–$13.81 | 5 |
| 2029 | $362M | $8.71 | $2.50–$14.19 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
AnaptysBio, Inc. Common Stock
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
www.anaptysbio.com- Employees
- 104
- IPO / List date
- Jan 26, 2017
- HQ
- SAN DIEGO, CA
Held by traders on TradeandTell
No one on the platform currently holds ANAB.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 90,900 | $5.0M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded ANAB yet.
